Wan Shengfeng, Wan Shengkai, Jiao Xiaojing, Cao Huixia, Gu Yue, Yan Lei, Zheng Yan, Niu Peiyuan, Shao Fengmin
Department of Nephrology, Henan Provincial Key Laboratory of Kidney Disease and Immunology, Henan Provincial People's Hospital (Zhengzhou University People's Hospital), Zhengzhou, China.
Department of Operations Management, Henan Provincial People's Hospital (Zhengzhou University People's Hospital), Zhengzhou, China.
FASEB J. 2021 Feb;35(2):e21367. doi: 10.1096/fj.202002334R.
Millions of human deaths occur annually due to chronic kidney disease, caused by diabetic kidney disease (DKD). Despite having effective drugs controlling the hyperglycemia and high blood pressure, the incidence of DKD is increasing, which indicates the need for the development of novel therapies to control DKD. In this article, we discussed the recent advancements in the basic innate immune mechanisms in renal tissues triggered under the diabetes environment, leading to the pathogenesis and progression of DKD. We also summarized the currently available innate immune molecules-targeting therapies tested against DKD in clinical and preclinical settings, and highlighted additional drug targets that could potentially be employed for the treatment of DKD. The improved understanding of the disease pathogenesis may open avenues for the development of novel therapies to rein in DKD, which consequently, can reduce morbidity and mortality in humans in the future.
每年有数百万人死于由糖尿病肾病（DKD）引起的慢性肾病。尽管有控制高血糖和高血压的有效药物，但DKD的发病率仍在上升，这表明需要开发控制DKD的新疗法。在本文中，我们讨论了糖尿病环境下肾组织中触发的基本先天免疫机制的最新进展，这些进展导致了DKD的发病机制和进展。我们还总结了目前在临床和临床前环境中针对DKD测试的针对先天免疫分子的可用疗法，并强调了可能用于治疗DKD的其他药物靶点。对疾病发病机制的更好理解可能为开发控制DKD的新疗法开辟道路，从而在未来降低人类的发病率和死亡率。
